Exosome of MSC

PreclinicalBiologic

FFujian Medical University

Exosome of MSC is one of 11 biologic programs targeting Aortic dissection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Aortic DissectionActive, not recruiting

Aortic DissectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

18 competitors in Aortic Dissection

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

1 2

Toradol

JJavelin Pharmaceuticals

Phase 3

1 3

Radicava

Shionogi

Preclinical

1 4

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

3 5

Xe-133

NNobilis Therapeutics Inc.

Preclinical

1 6

Cyklokapron

AAmring

Preclinical

1 7

Thrombosomes

CCellphire Therapeutics, Inc.

Phase 2

1 8

Drug

EElro Pharma

Preclinical

1 9

Blank Control

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Preclinical

1 10

Sivelestat Sodium

TThe First Hospital of Jilin University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

N/ANot yet recruiting

Aortic Dissection

NCT04356300

Clinical

Trials by Indication[1]

Aortic dissection1 trial

Exosome of Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection

Not yet recruiting·FFujian Medical University·N/A·NCT04356300·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Exosome of MSC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Exosome of MSC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Exosome of MSC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fujian Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: FFujian Medical University

Exosome of MSC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Aortic dissection1 trial

References

Drug Info

Quick Facts

Related News